Laurence Ehrlich, MD
Internal Medicine · Boynton Beach, FLNPI 1508823402
Payments from drug & device makers
Across 206 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$792
- Lilly USA, LLC$432
- Pfizer$419
- Amgen$388
- Novo Nordisk$310
- Abbott$238
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,674100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $792 |
| Lilly USA, LLC | 23 | $432 |
| Pfizer | 17 | $419 |
| Amgen(2 entities) | 13 | $388 |
| Novo Nordisk | 16 | $310 |
| Abbott | 7 | $238 |
| Boehringer Ingelheim | 7 | $229 |
| Exact Sciences | 8 | $211 |
| GSK | 11 | $209 |
| Amarin Pharma, Inc. | 9 | $148 |
| AbbVie | 6 | $130 |
| Progenics Pharmaceuticals, Inc. | 1 | $127 |
| Novartis | 6 | $113 |
| Edwards Lifesciences | 2 | $113 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Merck | 4 | $59 |
| Johnson & Johnson | 4 | $54 |
| Lundbeck LLC | 2 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Organogenesis Inc. | 1 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Viatris Specialty LLC | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Almatica Pharma LLC | 1 | $30 |
| Biogen | 1 | $29 |
| Dexcom, Inc. | 1 | $24 |
| Intra-sana Laboratories | 1 | $23 |
| Smith+Nephew | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Insightec,inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PYLARIFY$127
- BREZTRI$122
- JARDIANCE$114
- Repatha$109
- FREESTYLE LIBRE 3$104
How this compares
$4,674 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $151,643 |
| OzempicSemaglutide | 110 | $123,954 |
| MounjaroTirzepatide | 93 | $96,605 |
| JardianceEmpagliflozin | 81 | $94,143 |
| FarxigaDapagliflozin Propanediol | 88 | $90,508 |
| XareltoRivaroxaban | 52 | $66,514 |
| NuplazidPimavanserin Tartrate | 13 | $63,636 |
| TrulicityDulaglutide | 53 | $60,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $53,276 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $30,423 |
| EntrestoSacubitril/Valsartan | 14 | $23,610 |
| Repatha SureclickEvolocumab | 16 | $21,454 |
| BrilintaTicagrelor | 22 | $18,567 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $14,791 |
| JanuviaSitagliptin Phosphate | 12 | $14,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $432 | $156,942146 claims |
| PfizerEliquis | $419 | $151,643126 claims |
| Novo NordiskOzempic | $310 | $123,954110 claims |
| AstraZenecaFarxiga, Brilinta | $792 | $109,075110 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $229 | $101,18893 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $209 | $77,19682 claims |
| Johnson & JohnsonXarelto | $54 | $66,51452 claims |
| NovartisEntresto | $113 | $23,61014 claims |
| MerckJanuvia | $59 | $14,01612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $4,280390 claims |
| AbbVieSynthroid | $130 | $3,50459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Boynton Beach
- Debra WeinsteinBoynton Beach$14.8M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.